Results 91 to 100 of about 14,825 (199)
, 2017 A sudden and severe drug-induced decrease in plasma high-density lipoprotein cholesterol (HDL-C) is a rare condition. We report 2 patients with familial hypercholesterolemia treated with statins and fibrates and 2 others with mixed dyslipidemia treated ...
Krempf, Michel +3 more
core +1 more source
Fibrates down-regulate hepatic scavenger receptor class B type I protein expression in mice
, 2003 Fibrates are normolipidemic drugs used in atherogenic dyslipidemia because of their ability to raise high density lipoprotein (HDL) and decrease triglyceride levels.
Kozarsky, KF +12 more
core +1 more source
The PROMINENT trial: swan song of the fibrates
, 2023 Post hoc analyses of previous fibrate trials have suggested that individuals with type 2 diabetes mellitus with high triglyceride levels and low HDL-cholesterol levels benefit from fibrate therapy even when the overall trial results were neutral. However
Martens, Fabrice M.A.C. +2 more
core
Systematic review and meta-analysis deciphering the impact of fibrates on paraoxonase-1 status
, 2016 Systematic review and meta-analysis deciphering the impact of fibrates on paraoxonase-1 statusObjective A significant residual cardiovascular risk is consistently observed in patients treated with statins.
Jordi Camps; Amirhossein Sahebkar; Anna Hernández-Aguilera; David Abelló; Elena Sancho; Jorge Joven
core +1 more source
MOESM6 of Statins and/or fibrates for diabetic retinopathy: a systematic review and meta-analysis
, 2019 Additional file 6. Summary of findings table (fibrates compared to placebo for diabetic retinopathy)
Vânia Mozetic (7842722) +3 more
core +1 more source
The molecular mechanism by which hypolipidemic fibrates and antidiabetic thiazolidinediones exert their hypotriglyceridemic action are discussed.
Staels, B. +3 more
core +1 more source
Fibrates for Primary Biliary Cholangitis: What’s All the Hype?
, 2017 Ursodeoxycholic acid is the first-line therapy for primary biliary cholangitis. However, a subset of patients fail to show biochemical response. For these patients, adjuvant therapies are warranted. Obeticholic acid was conditionally approved as a second-
Cynthia Levy, Levy, Cynthia
core +1 more source
BAR502/fibrate conjugates: synthesis, biological evaluation and metabolic profile
Frontiers in ChemistryBAR502, a bile acid analogue, is active as dual FXR/GPBAR1 agonist and represents a promising lead for the treatment of cholestasis and NASH. In this paper we report the synthesis and the biological evaluation of a library of hybrid compounds prepared by
Claudia Finamore +11 more
doaj +1 more source
Fibrates : Do They Still Have a Role in Therapy in 2025?
Purpose of Review: Atherosclerotic cardiovascular disease (ASCVD) remains a leading cause of mortality despite opti mal LDL-C control, leaving substantial residual risk in patients with atherogenic dyslipidaemia.
Pirillo, Angela +2 more
core +1 more source